jama tirzepatide In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress #WCCardio Semaglutide and #tirzepatide have improved

The real question is: which approach works better

The unabsorbed l-carnitine travels down the gastrointestinal tract and reaches the colon

Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age 60 years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies

Following several years of what many practitioners called a regulatory winter for peptide therapies, recent announcements from the Department of Health and Human Services and the Food and Drug Administration have signaled a massive shift in policy

Thain A, Hart K, Ahmadi KR European journal of clinical nutrition 2025

The results are presented in tables and schemes